



NASEM Methadone Workshop

Kristi O'Malley

Senior Advisor

DRUG ENFORCEMENT ADMINISTRATION

March 3, 2022

DEA Supports Medication Assisted Treatment

DEA helps those who are harmed by drug trafficking and relentlessly pursues those who cause the harm. In this spirit, DEA is committed to doing all it can to **expand access** to medically assisted treatment to help those suffering from substance use disorder.

The Administration, DOJ, DEA, and HHS, among many others, are focused on efforts to improve use of MAT in order to reduce overdose deaths and help those suffering from opioid use disorder to recover.



DEA Supports Medication Assisted Treatment

DEA is working within its authority to improve access to treatment options, principally to expand access to methadone (schedule II) and buprenorphine (schedule III) for medication assisted treatment.

- COVID-19 Public Health Emergency Flexibilities (3/2020)
 - Take home methadone for stable patients
 - Audio-only Induction with Buprenorphine
 - Guidance to Wholesalers
- Dispensing MAT for administration (11/2020)
- HHS Practice Guidelines (4/2021)
- OTPs operating mobile components (6/2021)



DEA Supports Medication Assisted Treatment

Partnerships with Public Health stakeholders and experts in the field is critical in allaying concerns that law enforcement does not support MAT

- Partnered with SAMHSA and BOP expansion of MAT in Correctional facilities (6/2021)
 - Implementation of the Hub and Spoke Model
 - Assisting NY State Correction Facilities Implement Similar Model
- Partnership with HHS Opioid Rapid Response Program (ORRP) (9/2021)
- Partnered with SAMHSA for the Region 3 Suboxone[®] Summit (1/2022)
- Targeted Pharmacy/Pharmacist “Outreach” (3/2022)

